Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
Ryan Allway August 17th, 2022 Psychedelics, Top News TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced... Read more
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
Ryan Allway June 27th, 2022 Psychedelics, Top News — Marks the first novel psilocybin analog to enter clinical development —— Patient recruitment to commence immediately —— Pharmacokinetic and safety data readout expected in Q4 2022 — TORONTO, June 27, 2022–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )